Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Stock Has Consensus Price Target of $8.33 According to Brokerages

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) has been given a consensus rating of “Moderate Buy” by the five ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $8.33.

RANI has been the topic of a number of recent analyst reports. Weiss Ratings upgraded Rani Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 30th. HC Wainwright reissued a “buy” rating on shares of Rani Therapeutics in a research note on Tuesday, October 6th. Finally, Chardan Capital restated a “buy” rating on shares of Rani Therapeutics in a report on Thursday, October 22nd.

Rani Therapeutics Trading Up 1.4%

Rani Therapeutics stock opened at $0.57 on Thursday. Rani Therapeutics has a 12-month low of $0.51 and a 12-month high of $2.15. The firm has a 50-day moving average price of $0.72 and a 200-day moving average price of $0.90. The firm has a market capitalization of $79.18 million, a PE ratio of -2.99 and a beta of 0.61.

Rani Therapeutics (NASDAQ:RANI) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The business had revenue of $1.71 million during the quarter, compared to the consensus estimate of $1.28 million. Rani Therapeutics had a negative net margin of 493.00% and a negative return on equity of 76.64%. As a group, sell-side analysts predict that Rani Therapeutics will post -0.17 earnings per share for the current fiscal year.

Institutional Trading of Rani Therapeutics

An institutional investor recently raised its position in Rani Therapeutics stock. Squarepoint Ops LLC boosted its position in shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) by 155.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 41,902 shares of the company’s stock after purchasing an additional 25,501 shares during the quarter. Squarepoint Ops LLC’s holdings in Rani Therapeutics were worth $32,000 as of its most recent filing with the Securities & Exchange Commission. 30.19% of the stock is currently owned by institutional investors and hedge funds.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company developing technology designed to deliver biologic medicines orally. Its proprietary RaniPill platform is an ingestible robotic capsule intended to transport biologic drugs through the stomach and release them into the small intestine, where they can be absorbed into the bloodstream. The approach is intended to address the limitations of many biologic therapies, which are commonly administered by injection or infusion. The company is advancing the RaniPill platform for potential use with a range of large-molecule medicines, including peptides, proteins and antibodies.